187 related articles for article (PubMed ID: 30589164)
1. An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.
D'Ascenzio M; Pugh KM; Konietzny R; Berridge G; Tallant C; Hashem S; Monteiro O; Thomas JR; Schirle M; Knapp S; Marsden B; Fedorov O; Bountra C; Kessler BM; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(4):1007-1012. PubMed ID: 30589164
[TBL] [Abstract][Full Text] [Related]
2. Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells.
Li X; Wu Y; Tian G; Jiang Y; Liu Z; Meng X; Bao X; Feng L; Sun H; Deng H; Li XD
J Am Chem Soc; 2019 Jul; 141(29):11497-11505. PubMed ID: 31246451
[TBL] [Abstract][Full Text] [Related]
3. Biochemical profiling of histone binding selectivity of the yeast bromodomain family.
Zhang Q; Chakravarty S; Ghersi D; Zeng L; Plotnikov AN; Sanchez R; Zhou MM
PLoS One; 2010 Jan; 5(1):e8903. PubMed ID: 20126658
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
[TBL] [Abstract][Full Text] [Related]
5. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
6. Binding Mode of Acetylated Histones to Bromodomains: Variations on a Common Motif.
Marchand JR; Caflisch A
ChemMedChem; 2015 Aug; 10(8):1327-33. PubMed ID: 26033856
[TBL] [Abstract][Full Text] [Related]
7. Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
Clegg MA; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Leveridge M; Lindon M; Liwicki GM; Michon AM; Molnar J; Rioja I; Soden PE; Theodoulou NH; Werner T; Tomkinson NCO; Prinjha RK; Humphreys PG
J Med Chem; 2020 Jun; 63(11):5816-5840. PubMed ID: 32410449
[TBL] [Abstract][Full Text] [Related]
8. Structural ramification for acetyl-lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex.
Singh M; Popowicz GM; Krajewski M; Holak TA
Chembiochem; 2007 Jul; 8(11):1308-16. PubMed ID: 17582821
[TBL] [Abstract][Full Text] [Related]
9. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
Smith SG; Zhou MM
ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
[TBL] [Abstract][Full Text] [Related]
10. Structure and acetyl-lysine recognition of the bromodomain.
Mujtaba S; Zeng L; Zhou MM
Oncogene; 2007 Aug; 26(37):5521-7. PubMed ID: 17694091
[TBL] [Abstract][Full Text] [Related]
11. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
[TBL] [Abstract][Full Text] [Related]
12. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
13. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
14. The bromodomain: from epigenome reader to druggable target.
Sanchez R; Meslamani J; Zhou MM
Biochim Biophys Acta; 2014 Aug; 1839(8):676-85. PubMed ID: 24686119
[TBL] [Abstract][Full Text] [Related]
15. Lysine acetylation and the bromodomain: a new partnership for signaling.
Yang XJ
Bioessays; 2004 Oct; 26(10):1076-87. PubMed ID: 15382140
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain Histone Readers and Cancer.
Jain AK; Barton MC
J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
[TBL] [Abstract][Full Text] [Related]
17. Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine.
Engelberg IA; Foley CA; James LI; Frye SV
Curr Opin Chem Biol; 2021 Aug; 63():132-144. PubMed ID: 33852996
[TBL] [Abstract][Full Text] [Related]
18. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.
Vidler LR; Brown N; Knapp S; Hoelder S
J Med Chem; 2012 Sep; 55(17):7346-59. PubMed ID: 22788793
[TBL] [Abstract][Full Text] [Related]
19. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
20. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
